

References

I-21

1. Herceptin (trastuzumab) for injection, for intravenous use [package insert]. Genentech, Inc. South San Francisco, CA. Revised 02/2021.
2. Tse Hui L, Soon Tiong Lim A, Aye Aye T, et al. Implications of the updated 2013 American Society of Clinical Oncology/College of American Pathologists guideline recommendations on human epidermal growth factor receptor 2 gene testing using immunohistochemistry and fluorescence in situ hybridization for breast cancer. *Archives of Pathology & Laboratory Medicine*. 2016;140(2):140-147.
3. Denduluri N, Somerfield M, Wolff A. Selection of optimal adjuvant chemotherapy regimens for early breast cancer and adjuvant targeted therapy for HER2-positive breast cancers: An American Society of Clinical Oncology guideline adaptation of the Cancer Care Ontario Clinical Practice Guideline Summary. *Journal Of Oncology Practice*. 2016;12(5):485-488.
4. Herzuma (trastuzumab-pkrb) for injection, for intravenous use [package insert]. Teva Pharmaceuticals USA, Inc. North Wales, PA. Revised 06/2019.
5. Ogivri (trastuzumab-dkst) for injection, for intravenous use [package insert]. Mylan. Rockford, IL. Revised 02/2021.
6. Ontruzant (trastuzumab-dttb) for injection, for intravenous use [package insert]. Merck & Co., Inc. Whitehouse Station, NJ. Revised 06/2021.
7. Trazimera (trastuzumab-qyyp) injection, for intravenous use [package insert]. Pfizer Inc. New York, NY. Revised 11/2020.
8. Herceptin Hylecta (trastuzumab and hyaluronidase-oysk) injection, for subcutaneous use [package insert]. Genentech, Inc. San Francisco, CA. Revised 02/2019.
9. Privitera G, Luca T, Musso N, et al. In vitro antiproliferative effect of trastuzumab (Herceptin®) combined with cetuximab (Erbix®) in a model of human non-small cell lung cancer expressing EGFR and HER2. *Clinical And Experimental Medicine*. 2016;16(2):161-168.
10. National Comprehensive Cancer Network (NCCN). NCCN Drugs and Biologics Compendium®. 2022. Trastuzumab.
11. Clinical Pharmacology Compendia™. 2024. Tampa FL: Gold Standard, Inc. Trastuzumab.
12. Micromedex DrugDex Compendium®. 2024. Trastuzumab.
13. Kanjinti (trastuzumab-anns) for injection, for intravenous use [package insert]. Amgen Inc. Thousand Oaks, CA. Revised 10/2022.
14. Murthy RK, Loi S, Okines A, et al. Tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer. *NEJM*. 2020;382:597-609.
15. Jung KH, Ataseven B, Verrill M, et al. Adjuvant subcutaneous trastuzumab for HER2-positive early breast cancer: Subgroup analyses of safety and active medical conditions by body weight in the SafeHer phase III study. *Oncologist*. 2018;23(10):1137-1143.
16. Rugo HS, Barve A, Waller CF, et al. Effect of a proposed trastuzumab biosimilar compared with trastuzumab on overall response rate in patients with ERBB2 (HER2)-positive metastatic breast cancer: a randomized clinical trial. *JAMA*. 2017;317(1):37-47.
17. Micromedex DrugDex Compendium®. 2024. Trastuzumab-anns.
18. Micromedex DrugDex Compendium®. 2024. Trastuzumab-dkst.

19. Micromedex DrugDex Compendium®. 2024. Trastuzumab-dttb.
20. Micromedex DrugDex Compendium®. 2024. Trastuzumab-pkrb.
21. Micromedex DrugDex Compendium®. 2024. Trastuzumab-qyyp.
22. Micromedex DrugDex Compendium®. 2024. Trastuzumab and hyaluronidase-oysk.
23. National Comprehensive Cancer Network (NCCN). NCCN Drugs and Biologics Compendium®. 2024. Trastuzumab-anns.
24. National Comprehensive Cancer Network (NCCN). NCCN Drugs and Biologics Compendium®. 2024. Trastuzumab-dkst.
25. National Comprehensive Cancer Network (NCCN). NCCN Drugs and Biologics Compendium®. 2024. Trastuzumab-dttb.
26. National Comprehensive Cancer Network (NCCN). NCCN Drugs and Biologics Compendium®. 2024. Trastuzumab-pkrb.
27. National Comprehensive Cancer Network (NCCN). NCCN Drugs and Biologics Compendium®. 2024. Trastuzumab-qyyp.
28. National Comprehensive Cancer Network (NCCN). NCCN Drugs and Biologics Compendium®. 2024. Trastuzumab and hyaluronidase-oysk.